GSK Increases Stake in Indian Subsidiary - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

GSK Increases Stake in Indian Subsidiary

ePT--the Electronic Newsletter of Pharmaceutical Technology

GlaxoSmithKline has increased its stake in its Indian subsidiary, GlaxoSmithKline Consumer Healthcare Ltd, from 43.2% to 72.5%. GSK hopes that the transaction will increase the company’s exposure to India, which it describes as a key emerging market. The tender offer for the shares was undertaken by GSk’s subsidiary in Singapore, GlaxoSmithKline Pte. Ltd.

The offer was first announced in November 2012 and commenced on 17 January 2013. According to a press statement, shareholders of GlaxoSmithKline Consumer Healthcare Ltd tendered shares representing 29.3% (12,319,749) of the total outstanding shares.

The offer of 3900 Indian Rupees ($73.22) values the transaction at approximately $90 million. The final payment for shares tendered and accepted will be completed on or before February 13 2013. After this point, GlaxoSmithKline Pte. Ltd, will acquire full beneficial ownership of the shares tendered in the offer.

In a statement, David Redfern, chief strategy office at GSK, said, “We are very pleased with the outcome of this transaction, which will further increase our exposure to a key emerging market. It is a significant vote of confidence in the long-term growth prospects of our Consumer Healthcare business in India.”


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here